Inhibikase IKT (Parkinson's) MK $33Mio -> 5Mrd+ bis Ende 2023(?!)
eröffnet am 24.01.22 11:02:17 von
neuester Beitrag 23.01.24 22:26:06 von
neuester Beitrag 23.01.24 22:26:06 von
Beiträge: 27
ID: 1.356.796
ID: 1.356.796
Aufrufe heute: 1
Gesamt: 2.531
Gesamt: 2.531
Aktive User: 0
ISIN: US45719W1062 · WKN: A2QAMK · Symbol: IQT
0,5500
EUR
-16,67 %
-0,1100 EUR
Letzter Kurs 30.06.23 Frankfurt
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 32,00 | +27,95 | |
| 0,5800 | +23,40 | |
| 6,1100 | +18,64 | |
| 5,9000 | +15,69 | |
| 0,8600 | +14,67 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2200 | -11,59 | |
| 14,750 | -14,14 | |
| 1,8775 | -14,17 | |
| 1,2600 | -16,00 | |
| 1.138,25 | -16,86 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 75.153.049 von soulist am 23.01.24 22:16:49Bahnd sich hier was an?
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
an hour ago
$IKT
Conference Announcement
Health Care
GlobeNewswire PR
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders in response to recent price volatility.
Dear Fellow Shareholders of Inhibikase Therapeutics:
We have watched, as have you, as the value of IKT has dropped dramatically in the last 8 trading sessions. Days of unusually high volume and steep declines in price have impacted the stock with no identifiable cause. We are continuing to advance our work in Parkinson's Disease, Chronic Myelogenous Leukemia (CML) and Multiple System Atrophy (MSA), and there is no new information concerning this work that we believe could account for the volatility in share price in recent days.
Let me first address risvodetinib (IkT-148009) in Parkinson's and related diseases. At the recent Movement Disorder Society (MDS) Congress in Copenhagen, Denmark (August 26-September 1, 2023), we presented safety and tolerability data across 119 people that reinforces our belief that risvodetinib is safe and well tolerated, and that there are no side effects of clinical significance at any dose or treatment duration measured to date. These data are presented in our corporate presentation on the Inhibikase website. At the Congress, we further detailed the changes in Parkinson's functional assessments relative to baseline in 2-3 patients at each of the 50, 100 and 200 mg doses. These data come from the 8 active and 3 placebo patients that had been enrolled prior to the FDA Clinical Hold placed on the 201 Trial in November, 2022. These data support the importance of the ongoing 201 Trial in untreated Parkinson's disease that restarted with its first enrolled patient in May, 2023 following the lifting of the Clinical Hold in January of this year. Presently, 28 of the 120 planned patients are in the consenting or screening process or already enrolled in the trial. As we recently announced, one participant has already completed the 12-week dosing period and is awaiting the opportunity to participate in the planned 12 month extension study.
The implementation of our patient outreach program and launch of our patient portal (www.the201trial.com) is also providing avenues for accelerating trial enrollment. The pre-qualification questionnaire acts as a filter through which potential participants can pass and directly contact a nearby site. During September, the pre-qualification process identified an additional 50 potential participants. We believe this approach will assist all sites in concentrating their consenting and screening efforts on individuals who already meet the basic criteria for enrollment. We are encouraged by these statistics as the public awareness of the 201 Trial grows amongst the untreated Parkinson's patient community and their caregivers and support networks.
We also presented evidence for the wider applicability of risvodetinib to other Parkinson's-related disease at the MDS Congress, showing functional benefit in models of Multiple System Atrophy (MSA), an orphan disease that is a rapidly progressing form of Parkinsonism.
Finally, we continue to make significant progress on the path to approval of IkT-001Pro in Stable Phase Chronic Myelogenous Leukemia. IkT-001Pro is our prodrug of the anticancer agent imatinib mesylate. We have completed the necessary steps to request an FDA meeting to seek agreement on the path to approval under the 505(b)(2) regulation. Simultaneously, we continue to differentiate IkT-001Pro from standard-of-care by measuring bioequivalence to 600 mg imatinib mesylate, a dose for standard-of-care imatinib mesylate which is commonly in use, but poorly tolerated by patients. This high dose cohort is expected to be completed early in the 4th quarter of 2023.
Collectively, we are excited by the recent accomplishments across our programs and remain on track with our stated milestones. We are continuing to work diligently to increase our Company's value and educate investors on the progress we are making. Our cash position remains sufficient to fund our operations into the fourth quarter of 2024. We appreciate the continued support of our shareholders as we seek to reconcile the disconnect between our accomplishments, the potential significance of risvodetinib as a transformative treatment for Parkinson's disease and the recent decline in the Company's market valuation.
Sincerely,
Milton H. Werner, PhD.
President & CEO
https://quantisnow.com/insight/4979863
an hour ago
$IKT
Conference Announcement
Health Care
GlobeNewswire PR
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders in response to recent price volatility.
Dear Fellow Shareholders of Inhibikase Therapeutics:
We have watched, as have you, as the value of IKT has dropped dramatically in the last 8 trading sessions. Days of unusually high volume and steep declines in price have impacted the stock with no identifiable cause. We are continuing to advance our work in Parkinson's Disease, Chronic Myelogenous Leukemia (CML) and Multiple System Atrophy (MSA), and there is no new information concerning this work that we believe could account for the volatility in share price in recent days.
Let me first address risvodetinib (IkT-148009) in Parkinson's and related diseases. At the recent Movement Disorder Society (MDS) Congress in Copenhagen, Denmark (August 26-September 1, 2023), we presented safety and tolerability data across 119 people that reinforces our belief that risvodetinib is safe and well tolerated, and that there are no side effects of clinical significance at any dose or treatment duration measured to date. These data are presented in our corporate presentation on the Inhibikase website. At the Congress, we further detailed the changes in Parkinson's functional assessments relative to baseline in 2-3 patients at each of the 50, 100 and 200 mg doses. These data come from the 8 active and 3 placebo patients that had been enrolled prior to the FDA Clinical Hold placed on the 201 Trial in November, 2022. These data support the importance of the ongoing 201 Trial in untreated Parkinson's disease that restarted with its first enrolled patient in May, 2023 following the lifting of the Clinical Hold in January of this year. Presently, 28 of the 120 planned patients are in the consenting or screening process or already enrolled in the trial. As we recently announced, one participant has already completed the 12-week dosing period and is awaiting the opportunity to participate in the planned 12 month extension study.
The implementation of our patient outreach program and launch of our patient portal (www.the201trial.com) is also providing avenues for accelerating trial enrollment. The pre-qualification questionnaire acts as a filter through which potential participants can pass and directly contact a nearby site. During September, the pre-qualification process identified an additional 50 potential participants. We believe this approach will assist all sites in concentrating their consenting and screening efforts on individuals who already meet the basic criteria for enrollment. We are encouraged by these statistics as the public awareness of the 201 Trial grows amongst the untreated Parkinson's patient community and their caregivers and support networks.
We also presented evidence for the wider applicability of risvodetinib to other Parkinson's-related disease at the MDS Congress, showing functional benefit in models of Multiple System Atrophy (MSA), an orphan disease that is a rapidly progressing form of Parkinsonism.
Finally, we continue to make significant progress on the path to approval of IkT-001Pro in Stable Phase Chronic Myelogenous Leukemia. IkT-001Pro is our prodrug of the anticancer agent imatinib mesylate. We have completed the necessary steps to request an FDA meeting to seek agreement on the path to approval under the 505(b)(2) regulation. Simultaneously, we continue to differentiate IkT-001Pro from standard-of-care by measuring bioequivalence to 600 mg imatinib mesylate, a dose for standard-of-care imatinib mesylate which is commonly in use, but poorly tolerated by patients. This high dose cohort is expected to be completed early in the 4th quarter of 2023.
Collectively, we are excited by the recent accomplishments across our programs and remain on track with our stated milestones. We are continuing to work diligently to increase our Company's value and educate investors on the progress we are making. Our cash position remains sufficient to fund our operations into the fourth quarter of 2024. We appreciate the continued support of our shareholders as we seek to reconcile the disconnect between our accomplishments, the potential significance of risvodetinib as a transformative treatment for Parkinson's disease and the recent decline in the Company's market valuation.
Sincerely,
Milton H. Werner, PhD.
President & CEO
https://quantisnow.com/insight/4979863
JUL 14, 2023
Investor Presentation - 3Q 2023 | BUSINESS PRESENTATION
https://d1io3yog0oux5.cloudfront.net/_8da9e3a3e967bc7d6d696f…
JUL 17, 2023 4:05PM EDT
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
JUN 29, 2023 9:29AM EDT
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
Investor Presentation - 3Q 2023 | BUSINESS PRESENTATION
https://d1io3yog0oux5.cloudfront.net/_8da9e3a3e967bc7d6d696f…
JUL 17, 2023 4:05PM EDT
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
JUN 29, 2023 9:29AM EDT
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Tue, May 16, 2023, 07:45 am ET - 2 hours ago
BOSTON and ATLANTA, May 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that the first patient has been dosed in its Phase 2 '201' trial evaluating IkT-148009, the Company's novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease.
"Dosing of the first patient in our '201' trial completes the first milestone in our revamped Phase 2 program evaluating the clinical benefit of IkT-148009 for the treatment of Parkinson's disease and related disorders," commented Milton H. Werner, Ph.D., President and Chief Executive Officer.
https://www.stonkmoon.com/news/IKT/7009cc850b1b6d32f28ae1f0c…
Tue, May 16, 2023, 07:45 am ET - 2 hours ago
BOSTON and ATLANTA, May 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that the first patient has been dosed in its Phase 2 '201' trial evaluating IkT-148009, the Company's novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease.
"Dosing of the first patient in our '201' trial completes the first milestone in our revamped Phase 2 program evaluating the clinical benefit of IkT-148009 for the treatment of Parkinson's disease and related disorders," commented Milton H. Werner, Ph.D., President and Chief Executive Officer.
https://www.stonkmoon.com/news/IKT/7009cc850b1b6d32f28ae1f0c…
Trading Spotlight
FDA, was sollte dann das ganze Theater? 
Inhibikase Therapeutics Announces
FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
Wed, Jan 25, 2023, 08:05 am ET
- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses-
-Additional safety and pharmacokinetic information will be measured in healthy subjects at the 200 mg dose prior to implementation in the 201 trial-
https://www.stonkmoon.com/news/IKT/f386125ff2f68465f895d8e8f…
Inhibikase Therapeutics Announces
FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
Wed, Jan 25, 2023, 08:05 am ET
- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses-
-Additional safety and pharmacokinetic information will be measured in healthy subjects at the 200 mg dose prior to implementation in the 201 trial-
https://www.stonkmoon.com/news/IKT/f386125ff2f68465f895d8e8f…
Antwort auf Beitrag Nr.: 72.708.629 von soulist am 08.11.22 09:03:14Oder wie Relief Therapeutics..... Zum kotzen
Antwort auf Beitrag Nr.: 72.706.760 von Schumlim999 am 07.11.22 19:21:24
Ganz bitter, zumal selbst Milton bislang nichts genaues erfahren hat, was die FDA zu bemängeln hat. Mein Verdacht erhärtet sich, dass in den Anträgen eine oder zwei Heftklammern falsch gesetzt worden sind...
Fragt man sich doch, was da hinter den Kulissen gespielt wird - erinnert mich an Novavax vs. die mRNA Mixer mit der FDA als Ringrichter
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
Mon, November 7, 2022 at 2:00 PM
BOSTON and ATLANTA, Nov. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company was informed via e-mail communication that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-148009 for the treatment of Multiple Systems Atrophy (MSA) and has issued a Clinical Hold on the IkT-148009 201 program in Parkinson's disease (PD) and the use of IkT-148009 in MSA. The FDA indicated it will provide an official clinical hold letter to Inhibikase within 30 days.
"We have not seen any serious adverse events in the ongoing 201 trial and we remain committed to our mission to improve the lives of patients suffering from devastating neurodegenerative diseases," commented Milton H. Werner, Ph.D., President and Chief Executive Officer. "Given the safety, tolerability and pharmacokinetics data observed in clinical trials with IkT-148009 to date, we are actively working with the FDA to understand the agency's concerns and to resolve them as soon as possible."
Zitat von Schumlim999: Heute kam einer.......
Ganz bitter, zumal selbst Milton bislang nichts genaues erfahren hat, was die FDA zu bemängeln hat. Mein Verdacht erhärtet sich, dass in den Anträgen eine oder zwei Heftklammern falsch gesetzt worden sind...
Fragt man sich doch, was da hinter den Kulissen gespielt wird - erinnert mich an Novavax vs. die mRNA Mixer mit der FDA als Ringrichter
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
Mon, November 7, 2022 at 2:00 PM
BOSTON and ATLANTA, Nov. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company was informed via e-mail communication that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-148009 for the treatment of Multiple Systems Atrophy (MSA) and has issued a Clinical Hold on the IkT-148009 201 program in Parkinson's disease (PD) and the use of IkT-148009 in MSA. The FDA indicated it will provide an official clinical hold letter to Inhibikase within 30 days.
"We have not seen any serious adverse events in the ongoing 201 trial and we remain committed to our mission to improve the lives of patients suffering from devastating neurodegenerative diseases," commented Milton H. Werner, Ph.D., President and Chief Executive Officer. "Given the safety, tolerability and pharmacokinetics data observed in clinical trials with IkT-148009 to date, we are actively working with the FDA to understand the agency's concerns and to resolve them as soon as possible."
Heute kam einer.......
Antwort auf Beitrag Nr.: 72.281.538 von soulist am 26.08.22 15:44:49Der Booooom fehlt schon noch
Durchsuchen
